According to the recent statistics released by the Brazilian Health Surveillance Agency (ANVISA), 742 medicines were registered in Brazil in 2015, a 105 percent overall increase over 2014.

Among these, there has been a 116 percent increase in the authorization of generics over 2014 and a 286 percent increase in similar drugs.

Additionally, ANVISA has reported that in 2015 a license for the marketing of drugs for the treatment of hepatitis C was granted, and the first two biosimilar drugs as well as the first vaccine against dengue were registered.


Previously published 28 January 2016

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.